1. Quinacrine abolishes increases in cytoplasmic phospholipase A2 mRNA levels in the rat hippocampus after kainate-induced neuronal injury.
- Author
-
Ong WY, Lu XR, Ong BK, Horrocks LA, Farooqui AA, and Lim SK
- Subjects
- Animals, Blotting, Northern, Cytoplasm, Drug Interactions, Functional Laterality, Hippocampus cytology, Hippocampus metabolism, Male, Neurons enzymology, Phospholipases A drug effects, Phospholipases A genetics, Phospholipases A2, RNA, Messenger analysis, RNA, Messenger drug effects, Rats, Rats, Wistar, Time Factors, Triose-Phosphate Isomerase drug effects, Triose-Phosphate Isomerase genetics, Enzyme Inhibitors pharmacology, Excitatory Amino Acid Agonists toxicity, Hippocampus drug effects, Kainic Acid toxicity, Neurons drug effects, Phospholipases A metabolism, Quinacrine pharmacology
- Abstract
The present investigation was carried out to study the possible effects of quinacrine in modulating cytoplasmic phospholipase A(2) (cPLA(2)) mRNA levels in rat hippocampus after kainate treatment. Injections of kainate into the right lateral ventricle resulted in significant increases in cPLA(2) mRNA levels in the hippocampus, at 3 days and 7 days after injection. The elevation in cPLA(2) mRNA levels is consistent with previous observations of increased cPLA(2) immunoreactivity in degenerating neurons and astrocytes at these times. Rats that received once daily intraperitoneal injections of quinacrine (5 mg/kg) after the intracerebroventricular kainate injections showed almost complete attenuation of increased cPLA(2) expression, at both 3 and 7 days after kainate injection. These results show that in addition to its well-known effect of inhibition of PLA(2) activity, quinacrine could also inhibit cPLA(2) expression, and further supports a role for PLA(2) in kainate-induced neuronal injury.
- Published
- 2003
- Full Text
- View/download PDF